This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NN8555

Johnson & Johnson

Drug Names(s): Anti NKG2D, IPH 2301, NNC 0142-0000-0002, NNC-0142-002

Description: NN8555/IPH 2301 is a monoclonal antibody targeting natural killer cells and certain T cells, with a novel mechanism of action.

Deal Structure: Innate Pharma and Novo Nordisk
In April 2006, Innate and Novo Nordisk announced a partnership to develop new drugs targeting natural killer (NK) cells. As part of the agreement Novo Nordisk will invest 10 million euros in new Innate Pharma equity. The Innate Pharma/Novo Nordisk partnership is broadly strategic, involving wide-ranging R&D based on NK cell biology. According to the agreement, the companies will collaborate for at least the next three years to develop new molecules chiefly antibodies that stimulate or inhibit NK cell activity. Although the partnership covers all therapeutic indications, drug candidates will be developed primarily in cancer, autoimmune disorders and infections. This collaboration will seek to bring drug candidates through preclinical trials, at which point Novo Nordisk will have the main responsibility for clinical development and regulatory approval.

Both companies will contribute intellectual property rights, expertise and R&D...See full deal structure in Biomedtracker

Partners: Innate Pharma S.A. Novo Nordisk A/S


NN8555 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug